Jay Roberts has been the President and Chief Executive Officer of Vyant Bio, Inc. since 2018. Mr. Roberts had previously served as the Chief Operating Officer of Cancer Genetics. Prior to joining ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

We are initiating coverage of Vyant Bio, Inc. (NASDAQ:VYNT) assigning a valuation of $2.00 per share. Vyant is a drug discovery and development technology company that is focusing on ...

Vyant Bio Inc. is emerging as an advanced biotechnology drug discovery company. With capabilities in data, science (both biology and chemistry), engineering, and regulatory, the company is rapidly ...

CEO of Vyant Bio Inc (30-Year Financial, Insider Trades) John A Roberts (insider trades) bought 14,481 shares of VYNT on 05/26/2021 at an average price of $3.46 a share. The total cost of this ...

Biotechnology companies such as Biogen Inc. BIIB, Alector Inc. ALEC, Amylyx Pharmaceuticals Inc. AMLX and Addex Therapeutics Ltd. ADXN have heavily invested in developing therapies for ...

CHERRY HILL, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 20, 2023 (the ...

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vyant Bio (VYNT – Research Report) and Kymera Therapeutics (KYMR – Research Report) with bullish ...

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company’s central nervous system (CNS) drug discovery platform combines ...

Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...